AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03925493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart rate monitors
Description: Heart rate monitors (HRM) will be given to half of the patients randomly assigned to exercise stress testing group. Patients will receive a polar heart rate chest strap and polar watch. Patients will be asked to wear both, the chest strap and the watch during cardiac rehabilitation. Ultimately, we hope that the use of HRM is not necessary, but it may be needed to assure that patients in the THHR are able to consistently know their HR and adjust their exercise prescription. This will also increase the likelihood that there is a difference in heart rates between the THRR group from the RPE group.
Study NCT01322711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40 mg day
Study NCT01322711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diet
Study NCT02528461 — intervention group
Intervention type: DRUG
Intervention: Galactose
Description: A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
Study NCT02528461 — intervention group
Intervention type: PROCEDURE
Intervention: Gastroscopy
Study NCT02528461 — intervention group
Intervention type: PROCEDURE
Intervention: Liver biopsy
Study NCT02528461 — intervention group
Intervention type: PROCEDURE
Intervention: Fibroscan
Study NCT02528461 — intervention group
Intervention type: PROCEDURE
Intervention: Liver vein catheterization
Study NCT02528461 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir
Study NCT01920061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212384 (gedatolisib)
Description: PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
Study NCT01920061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m\^2
Study NCT01920061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m\^2
Study NCT01920061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
Study NCT01844310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAL+TDF+LPV/r
Description: Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
Study NCT01844310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3TC+TDF+LPV/r
Description: Group B will be assigned with 3TC+TDF+LPV/r
Study NCT00412425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palonosetron
Description: 0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
Study NCT00740766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food diary and behavioral model
Description: The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study.
Study NCT04439708 — intervention group
Intervention type: OTHER
Intervention: Blood and aqueous humor biomarker of treatment response
Description: Blood analyses and aqueous humor analysis
Study NCT01756482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5806
Description: GS-5806, powder for oral solution
Study NCT01756482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00283062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (TAXOTERE®) Chemotherapy
Description: 75 mg/m\^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy.
Study NCT00283062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Description: 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
Study NCT00283062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate ( ELIGARD®) Hormonal Therapy
Description: 22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
Study NCT02072525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: One dose administered intramuscularly (IM) in the upper right deltoid of the arm.
Study NCT02072525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23®
Description: One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
Study NCT02072525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13®
Description: One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
Study NCT04407065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double trigger
Description: Final follicular maturation is triggered by the co-administration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
Study NCT04407065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCG trigger
Description: Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
Study NCT01199276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
Study NCT01199276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
Study NCT01709201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
Study NCT02537405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939)
Description: Rivaroxaban granule 10mg for one day
Study NCT02537405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban (Xarelto, BAY 59-7939)
Description: Rivaroxaban tablet 10mg for one day
Study NCT02326766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KRG
Description: 5g Korea red ginseng (KRG)
Study NCT02326766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5g placebo
Study NCT00568113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylcysteine in arm 1
Description: Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy.
Study NCT00568113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylcysteine in arm 1
Description: Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy.
Study NCT03805516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCOPP-CW
Description: The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.
Study NCT03805516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.
Study NCT02562274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects are received placebo treatments once daily for 8 weeks
Study NCT03909451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT02562274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MP 50 mg/day
Description: Subjects are received MP 50 mg/day treatments once daily for 8 weeks
Study NCT03909451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT00955149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva)
Description: Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
Study NCT02610933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rivaroxaban
Description: replacement of vitamin K antagonist by rivaroxaban
Study NCT02610933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2
Description: Vitamin K2 supplementation
Study NCT00997620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate Nasal Spray 110 mcg
Description: Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.
Study NCT00997620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
Study NCT01281228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
Study NCT01281228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide + exendin (9-39)
Description: The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
Study NCT01281228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline infusion
Study NCT00506194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Study NCT00506194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OAD
Description: Gliclazide-MR, Metformin, Glimepiride
Study NCT04254029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MOROLSTEVER1
Description: The intervention consisted of a daily consummation of 425 ml of drink containing the extracts of 1,38mg of leaves extracts of moringa oleifera and 23,46 mg of stevia rebaudiana Bertoni leaves extracts lasting 45 days.
Study NCT04264143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infusate with MTX110 and gadolinium
Description: Pulses 1 and 2 will be prepared with 30, 60 or 90 uM concentration of MTX110. The infusate consists of gadolinium and MTX110 (30, 60, or 90 uM) at approximately 1:100 ratio.
Study NCT04264143 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Convection-Enhanced Delivery (CED)
Description: CED is the method by which the drug are delivered to the brain under controlled pressure to the brain by targeted micro-catheters.
Study NCT00599456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid vitamins
Description: Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
Study NCT00599456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo capsules,2 capsules, by mouth, daily for 3 months
Study NCT04008511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.
Study NCT04008511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.
Study NCT04008511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid po for 14 days.
Study NCT04008511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid po for 14 days.
Study NCT04008511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2, day 1, every 3 weeks
Study NCT04008511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130mg/m2, day 1, every 3 weeks
Study NCT02554214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glafkos drainage device
Study NCT01896271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
Study NCT01896271 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation Therapy
Description: SABR dose varying from 8Gy-20Gy in 1-3 fractions
Study NCT01824706 — intervention group
Intervention type: PROCEDURE
Intervention: craniectomy
Description: craniectomy
Study NCT02700594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Joint mobilization
Description: Mobilization and manipulation are manual therapy techniques comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement.16 The term joint mobilization, or nonthrust mobilization, often refers to slow, rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings.
Study NCT00665236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy
Description: Eight weekly 45-minute sessions with therapist
Study NCT00665236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low strength static magnets
Description: Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
Study NCT03255759 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Multiplex molecular diagnostic assay
Description: To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
Study NCT02322190 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis (ECP)
Description: Twice weekly for 1 month or Twice every other week for 2 months or Twice during one week per month for 4 months for a total of up to 7 months of treatment.
Study NCT02322190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxsalen
Description: Sterile solution used in conjunction with photopheresis procedure.
Study NCT03628755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluency Shaping Therapy
Description: FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.
Study NCT03628755 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluency Shaping Therapy
Description: FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.
Study NCT03628755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combination Group
Description: combination group intervention of DMT + FST
Study NCT03071978 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT with LV-only pacing / bi-ventricular pacing
Description: LV-fusion pacing group received cardiac resynchronization therapy with adaptive algorithm and disabled RV pacing. While BV pacing group received conventional cardiac resynchronization therapy without adaptive algorithm.
Study NCT03071978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT with LV-only pacing / bi-ventricular pacing
Description: LV-fusion pacing group received cardiac resynchronization therapy with adaptive algorithm and disabled RV pacing. While BV pacing group received conventional cardiac resynchronization therapy without adaptive algorithm.
Study NCT01393340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.~Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab.
Study NCT01393340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01216579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mannitol (an airway challenge agent)
Study NCT01216579 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mannitol (an airway challenge agent)
Study NCT01897142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
Study NCT01897142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study NCT01897142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
Study NCT01897142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study NCT01897142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 1 micrograms per kilogram of PF-05230907, IV bolus, single dose
Study NCT01897142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study NCT01897142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 2 micrograms per kilogram of PF-05230907, IV bolus, single dose
Study NCT01897142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for PF-05230907
Description: 2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
Study NCT01897142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: 3 micrograms per kilogram of PF-05230907, IV bolus, single dose